Repository logo
 
Publication

Immunotherapy in triple-negative breast cancer: the role of immune checkpoint inhibitors

2022-11Journal article Open access
Simple item page
dc.contributor.authorBranco, Susana
dc.contributor.authorGraça, Maria Inês
dc.contributor.authorMorais, Sara
dc.date.accessioned2023-05-30T09:51:03Z
dc.date.available2023-05-30T09:51:03Z
dc.date.issued2022-11
dc.description.abstractABSTRACT - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, associated with a poor prognosis in both early and advanced stages. Chemotherapy remains the standard treatment for these patients, despite its limited benefit. Due to the disease’s aggressive features and lack of targeted therapies, several attempts have been made to disclose novel molecular targets. TNBC is now known to be an immunogenic breast cancer subtype. Therefore, immunotherapy has emerged as a promising treatment option for this disease. During the last few years, immune checkpoint inhibitors (anti-PD1/PD-L1 and anti-CTLA-4 monoclonal antibodies) have been investigated either as monotherapy or combined with conventional therapy in TNBC. Herein, we review the status of immunotherapy in TNBC, focusing on the value of immune checkpoint inhibitors.pt_PT
dc.description.abstractRESUMO - O cancro de mama triplo-negativo (TNBC) é um subtipo agressivo de cancro de mama, associado a um mau prognóstico em estadios iniciais e avançados. A quimioterapia continua a ser o tratamento padrão preconizado para estes doentes, apesar de seu benefício limitado. Devido às características agressivas da doença e à falta de terapias dirigidas, várias tentativas foram feitas para investigar novos alvos moleculares. O TNBC é agora conhecido por ser um subtipo de cancro de mama imunogénico. Neste contexto, a imunoterapia surgiu como uma opção promissora de tratamento para esta doença. Durante os últimos anos, os inibidores de checkpoint imunológico (anti-PD1/PD-L1 e anti-CTLA-4 anticorpos monoclonais) foram investigados quer em monoterapia quer em combinação com a terapia convencional nesta neoplasia. Neste artigo apresenta-se uma revisão bibliográfica do papel da imunoterapia no contexto do TNBC, com enfoque no papel dos inibidores de checkpoint imunológico.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBranco S, Graça MI, Morais S. Immunotherapy in triple-negative breast cancer: the role of immune checkpoint inhibitors. Saúde & Tecnologia. 2022;(27):5-17.pt_PT
dc.identifier.doi10.25758/set.610pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16171
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherInstituto Politécnico de Lisboa, Escola Superior de Tecnologia da Saúde de Lisboapt_PT
dc.relation.publisherversionhttps://journals.ipl.pt/stecnologia/article/view/610pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectTriple-negative breast cancerpt_PT
dc.subjectTNBCpt_PT
dc.subjectImmune checkpoint inhibitorspt_PT
dc.subjectICIspt_PT
dc.subjectPD-L1pt_PT
dc.subjectPD-1pt_PT
dc.subjectCTLA-4pt_PT
dc.subjectCancro de mama triplo-negativopt_PT
dc.subjectInibidores de checkpoint imunológicopt_PT
dc.titleImmunotherapy in triple-negative breast cancer: the role of immune checkpoint inhibitorspt_PT
dc.title.alternativeImunoterapia no cancro de mama triplo-negativo: o papel dos inibidores de checkpoint imunológicopt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage17pt_PT
oaire.citation.issue27pt_PT
oaire.citation.startPage05pt_PT
oaire.citation.titleSaúde & Tecnologiapt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Immunotherapy in triple-negative breast cancer_the role of immune checkpoint inhibitors.pdf
Size:
865.56 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos